Increasing mortality due to end-stage liver disease in patients with humanimmunodeficiency virus infection

Highly active antiretroviral therapy has decreased human immunodeficiency v irus (HIV)-associated mortality; other comorbidities, such as chronic liver disease, are assuming greater importance. We retrospectively examined the causes of death of HIV-seropositive patients at our institution in 1991, 19 96, and 1998-1999. In 1998-1999, 11 (50%) of 22 deaths were due to end-stag e liver disease, compared with 3 (11.5%) of 26 in 1991 and 5 (13.9%) of 36 in 1996 (P = .003). In 1998-1999, 55% of patients had nondetectable plasma HIV RNA levels and/or CD4 cell counts of >200 cells/mm(3) within the year b efore death. Most of the patients that were tested had detectable antibodie s to hepatitis C virus (75% of patients who died in 1991, 57.7% who died in 1996, and 93.8% who died in 1998-1999; P = NS). In 1998-1999, 7 patients ( 31.8%) discontinued antiretroviral therapy because of hepatotoxicity, compa red with 0 in 1991 and 2 (5.6%) in 1996. End-stage liver disease is now the leading cause of death in our hospitalized HIV-seropositive population.